WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318908
CAS#: 322-79-2
Description: Triflusal is a platelet aggregation inhibitor. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Triflusal is indicated for the prevention of cardiovascular events such as stroke, acute treatment of cerebral infarction and myocardial infarction, and thromboprophylaxis due to atrial fibrillation.
Hodoodo Cat#: H318908
Name: Triflusal
CAS#: 322-79-2
Chemical Formula: C10H7F3O4
Exact Mass: 248.03
Molecular Weight: 248.155
Elemental Analysis: C, 48.40; H, 2.84; F, 22.97; O, 25.79
Synonym: Triflusal, Disgren, Grendis, Aflen, Triflux
IUPAC/Chemical Name: 2-acetyloxy-4-(trifluoromethyl)benzoic acid
InChi Key: RMWVZGDJPAKBDE-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
SMILES Code: O=C(O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 248.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: González-Correa JA, De La Cruz JP. Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24. Review. PubMed PMID: 16939630.
2: Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004296. Review. PubMed PMID: 16034926.
3: Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P. Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. Review. PubMed PMID: 19465361.
4: Murdoch D, Plosker GL. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs. 2006;66(5):671-92. Review. PubMed PMID: 16620146.
5: Alvarez Sabín J, Matías-Guiu J, Galiano L, Codina Puiggrós A. [The risk of hemorrhage in long-term use of aspirin and triflusal]. Rev Neurol. 1998 Dec;27(160):951-5. Review. Spanish. PubMed PMID: 9951011.
6: McNeely W, Goa KL. Triflusal. Drugs. 1998 Jun;55(6):823-33; discussion 834-5. Review. PubMed PMID: 9617597.
